ReviewInfection and immunity2021
The Host Cellular Immune Response to Infection by Campylobacter Spp. and Its Role in Disease.
Review in Infection and immunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Triggers of Guillain-Barré Syndrome:International journal of molecular sciences · 2022Pooled it
- Oxyberberine-nanoparticle attenuates the cognitive deficits in a transgenic mouse model of Alzheimer's disease via modulating gut microbiota through suppressing CXCL10/CXCR3 pathway.Acta pharmacologica Sinica · 2026Article
- Identification of Campylobactercoli as a key pathogen in Jinhua piglet diarrhea and its the probiotic control by Enterococcus faecium.BMC microbiology · 2026Article
- A case of chronic Campylobacter fetus infection-related glomerulonephritis, mimicking systemic autoimmune diseases.CEN case reports · 2026Article
- Antimicrobial and anti-inflammatory properties ofMicrobiology (Reading, England) · 2026Article
- A review of chronic enterocolitis of rhesus macaques (Frontiers in veterinary science · 2026Review
- Epithelial-Macrophage Crosstalk in Host Responses toMicroorganisms · 2025Article
- Cas9 modulatesMicrobiology (Reading, England) · 2025Article
- Unraveling the Pathophysiology of Irritable Bowel Syndrome: Mechanisms and Insights.International journal of molecular sciences · 2025Review
- Human milk oligosaccharides and Campylobacter jejuni and Campylobacter coli gastroenteritis risk in a Nicaraguan Birth Cohort.The American journal of clinical nutrition · 2025Article
- Determinants of Campylobacter species diversity in infants and association with family members, livestock, and household environments in rural Eastern Ethiopia.Gut pathogens · 2025Article
- Emergence of Multidrug-ResistantTropical medicine and infectious disease · 2025Article
- The disease and economic burden of notified and underestimated Campylobacter enteritis cases and associated sequelae in Germany.PloS one · 2025Article
- Consortium ofAntibiotics (Basel, Switzerland) · 2024Article
- Microbiome Shifts and Their Impact on Gut Physiology in Irritable Bowel Syndrome.International journal of molecular sciences · 2024Review
- Feeding intolerance after pediatric cardiac surgery is associated with dysbiosis, barrier dysfunction, and reduced short-chain fatty acids.American journal of physiology. Gastrointestinal and liver physiology · 2024Article
- Article
- Campylobacteriosis: A rising threat in foodborne illnesses.Open veterinary journal · 2024Review
- Article
- Carvacrol prophylaxis improves clinical outcome and dampens apoptotic and pro-inflammatory immune responses upon Campylobacter jejuni infection of human microbiota-associated IL-10-/- mice.European journal of microbiology & immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Campylobacter spp. are the leading cause of bacterium-derived gastroenteritis worldwide, impacting 96 million individuals annually. Unlike other bacterial pathogens of the gastrointestinal tract, Campylobacter spp. lack many of the classical virulence factors that are often associated with the ability to induce disease in humans, including an array of canonical secretion systems and toxins. Consequently, the clinical manifestations of human campylobacteriosis and its resulting gastrointestinal pathology are believed to be primarily due to the host immune response toward the bacterium. Further, while gastrointestinal infection is usually self-limiting, numerous postinfectious disorders can occur, including the development of Guillain-Barré syndrome, reactive arthritis, and irritable bowel syndrome. Because gastrointestinal disease likely results from the host immune response, the development of these postinfectious disorders may be due to dysregulation or misdirection of the same inflammatory response. As a result, it is becoming increasingly important to the Campylobacter field, and human health, that the cellular immune responses toward Campylobacter be better understood, including which immunological events are critical to the development of disease and the postinfectious disorders mentioned above. In this review, we collectively cover the cellular immune responses across susceptible hosts to Campylobacter jejuni infection, along with the tissue pathology and postinfectious disorders which may develop.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.